Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price was down 5.5% on Tuesday . The company traded as low as $21.61 and last traded at $21.77. Approximately 36,787 shares changed hands during trading, a decline of 87% from the average daily volume of 280,797 shares. The stock had previously closed at $23.04.

Analysts Set New Price Targets

A number of analysts recently weighed in on DNTH shares. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Finally, Oppenheimer increased their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Performance

The stock’s fifty day moving average price is $24.02 and its 200-day moving average price is $26.51. The firm has a market cap of $568.62 million, a PE ratio of -7.68 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Quest Partners LLC increased its holdings in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth about $236,000. SG Americas Securities LLC grew its holdings in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after buying an additional 4,506 shares in the last quarter. Fred Alger Management LLC grew its holdings in shares of Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after buying an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth about $265,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.